Abstract
Certain germline mutations in either BRCA1 or BRCA2 confer a lifetime risk of developing breast cancer that may approach 90% 1–3. The BRCA1 185delAG mutation was found in 20% and the BRCA2 6174delT mutation in 8% of Ashkenazi Jewish women with early-onset breast cancer4–6. The 185delAG mutation was observed in 0.9% of 858 Ashkenazi Jews unselected for a personal or family history of cancer7. Assuming comparable age-specific penetrances, a carrier frequency of 0.3% was estimated for the 6174delT BRCA2 mutation6. To test this hypothesis, we performed a population survey of 1,255 Jewish individuals. In two independent groups, a prevalence of approximately 1 % (C.I. 0.6–1.5) was observed for the 6174delT mutation. The relative risk of developing breast cancer by age 42 was estimated to be 9.3 (C.I. 2.5–22.5) for6174delT, compared to 31 (C.I. 11–77) for 185delAG. Analysis of 107 Ashkenazi Jewish women with breast cancer and a family history of breast or ovarian cancer confirmed a four-fold greater prevalence for the BRCA1 185delAG mutation compared to the BRCA2 6174delT mutation. Our findings suggest a difference in cumulative lifetime penetrance for the two mutations. Genetic counseling for the one in 50 Ashkenazi Jewish individuals harbouring specific germline mutations in BRCA1 or BRCA2 must be tailored to reflect the different risks associated with the two mutations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Easton, D. et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am. J. Hum Genet. 52, 678–701 (1993).
Wooster, R. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265, 2088–2090 (1994).
Miki, Y. et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994).
FitzGerald, M.G. et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N. Engl. J. Med. 334, 143–149 (1996).
Offit, K. et al. Germline BRCA1 185delAG mutations in Jewish women affected by breast cancer. Lancet 347, 1643–1645 (1996).
Neuhausen, S. et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet. 13, 126–128 (1996).
Struewing, J.P. et al.The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet. 11, 198–200 (1995).
Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).
Tavtigian, S.V. et al. The BRCA2 gene and mutations in 13q-linked kindreds. Nature Genet. 12, 333–337 (1996).
Simard, J. et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet. 8, 392–398 (1994).
Struewing, J.P. et al Detection of eight BRCA1 mutations in 10 breast ovarian cancer families including 1 family with male breast cancer Am.J.Hum Genet. 57, 1–7 (1995).
Tonin, P. et al.BRCA1 mutations in Ashkenazi Jewish Women. Am. J. Hum Genet. 57, 189 (1995).
Berman, D.B., Wagner-Costalas, J., Schultz, D.C., Lynch, H.T., Daly, M. & Godwin, A.K. Two distinct origins of a common BRCA1 mutation in breast ovarian cancer families: a genetic study of 15185delAG-mutation kindreds. Am.J.Hum Genet 58, 1166–1176 (1996).
Neuhausen, S.L. et al. Haplotypeand phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am. J. Hum Genet. 58, 271–280, (1996).
Kronn, D., Oddoux, C., Phillips, J. & Ostrer, H. The frequency of carriers for Canavan disease in the metropolitan New York Ashkenazi Jewish population. Am. J. Hum Genet. 57, 1250–1252, (1995).
Oddoux, C. et al. Prenatal diagnostic testing for familial dysautonomia using linked genetic markers. Prenat. Diagn. 15, 817–826 (1995).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oddoux, C., Struewing, J., Clayton, C. et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14, 188–190 (1996). https://doi.org/10.1038/ng1096-188
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng1096-188
This article is cited by
-
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
Genome Medicine (2022)
-
International trends in ovarian cancer incidence from 1973 to 2012
Archives of Gynecology and Obstetrics (2021)
-
Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis
Journal of Assisted Reproduction and Genetics (2020)
-
Mutations in context: implications of BRCA testing in diverse populations
Familial Cancer (2018)
-
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
British Journal of Cancer (2017)